Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

Background Approximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-ce...

Full description

Bibliographic Details
Main Authors: Patricia Pérez-Galán, Javier Melchor, Marcos Garcia-Lacarte, Sara C. Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco J. Novo, Juan Garcia Valero, Jose A. Martinez-Climent, Sergio Roa
Format: Article
Language:English
Published: BMJ Publishing Group 2023-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/2/e006113.full

Internet

https://jitc.bmj.com/content/11/2/e006113.full

Similar Items